Where Will CRISPR Therapeutics Be in 3 Years?
CRISPR Therapeutics (NASDAQ: CRSP) made a name for itself by pioneering advanced gene therapies made with technologies that ...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...
Swissinfo8d
Swiss researchers find unwanted CRISPR side effects
CRISPR gene editing can have unforeseen consequences on the structure of chromosomes, says the University of Zurich.
STAT24d
Editas tacks again, steering from lead sickle cell treatment to new one
the latest shift for a tarantella company that has repeatedly switched direction and leadership since first emerging as one of the first CRISPR biotechs a decade ago. Editas will now focus ...